Showing results (1-10 of 131) with videos related to
Sort By:
Pageof 14
Cancer Discovery|August 2, 2024
WRN Helicase: Is There More to MSI-H than Immunotherapy?Zev A WainbergCurrent Treatment Options in Oncology|February 8, 2011
Targeted therapies for metastatic esophagogastric cancerDeepa Reddy, Zev A WainbergGastrointestinal Cancer Research : GCR|January 20, 2010
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing TherapyPatrick Chun, Zev A WainbergExpert Opinion on Biological Therapy|June 13, 2015
The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitorsZev A Wainberg, Alexandra DrakakiExpert Review of Anticancer Therapy|July 14, 2007
Panitumumab in colorectal cancerZev A Wainberg, J Randolph HechtCancer Treatment Reviews|January 15, 2023
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature reviewFarshid Dayyani, Teresa Macarulla, Andrew Johnson, et al.Small (Weinheim an Der Bergstrasse, Germany)|May 15, 2020
Safety Considerations of Cancer Nanomedicine-A Key Step toward TranslationXiangsheng Liu, Ivanna Tang, Zev A Wainberg, et al.Clinical Advances in Hematology & Oncology : H&O|March 15, 2022
How quality of life can inform management decisions in later-line metastatic colorectal cancerTanios S Bekaii-Saab, Kanwal Raghav, Zev A WainbergJCO Clinical Cancer Informatics|January 19, 2019
Differences in Cancer-Specific Mortality of Right- Versus Left-Sided Colon Adenocarcinoma: A Surveillance, Epidemiology, and End Results Database AnalysisChenyang Wang, Zev A Wainberg, Ann Raldow, et al.Nature Reviews. Clinical Oncology|February 29, 2024
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directionsMasuko Katoh, Yohann Loriot, Giovanni Brandi, et al.Pageof 14